Cargando…
IL-31 induces antitumor immunity in breast carcinoma
BACKGROUND: Immunomodulatory agents that induce antitumor immunity have great potential for treatment of cancer. We have previously shown that interleukin (IL)-31, a proinflammatory cytokine from the IL-6 family, acts as an antiangiogenic agent. Here, we characterize the immunomodulatory effect of I...
Autores principales: | Kan, Tal, Feldman, Erik, Timaner, Michael, Raviv, Ziv, Shen-Orr, Shai, Aronheim, Ami, Shaked, Yuval |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7449545/ https://www.ncbi.nlm.nih.gov/pubmed/32843492 http://dx.doi.org/10.1136/jitc-2020-001010 |
Ejemplares similares
-
IL-6 contributes to metastatic switch via the differentiation of monocytic-dendritic progenitors into prometastatic immune cells
por: Magidey-Klein, Ksenia, et al.
Publicado: (2021) -
The antiangiogenic role of the pro-inflammatory cytokine interleukin-31
por: Davidi, Shiri, et al.
Publicado: (2017) -
Combining IL-2-based immunotherapy with commensal probiotics produces enhanced antitumor immune response and tumor clearance
por: Shi, Linlin, et al.
Publicado: (2020) -
Robust IL-2-dependent antitumor immunotherapy requires targeting the high-affinity IL-2R on tumor-specific CD8(+) T cells
por: LaPorte, Kathryn M, et al.
Publicado: (2023) -
TIM-3 blockade enhances IL-12-dependent antitumor immunity by promoting CD8(+) T cell and XCR1(+) dendritic cell spatial co-localization
por: Gardner, Alycia, et al.
Publicado: (2022)